Cargando…

Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo

Endometriosis, a disease of reproductive age women, is a major cause of infertility, menstrual disorders and pelvic pain. Little is known about its etiopathology, but chronic pelvic inflammation is a common feature in affected women. Beside symptomatic treatment of endometriosis-associated pain, onl...

Descripción completa

Detalles Bibliográficos
Autores principales: Khoufache, Khaled, Bazin, Sylvie, Girard, Karine, Guillemette, Julie, Roy, Marie-Christine, Verreault, Jean-Pierre, Al-Abed, Yousef, Foster, Warren, Akoum, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359359/
https://www.ncbi.nlm.nih.gov/pubmed/22649515
http://dx.doi.org/10.1371/journal.pone.0037264
_version_ 1782233870229307392
author Khoufache, Khaled
Bazin, Sylvie
Girard, Karine
Guillemette, Julie
Roy, Marie-Christine
Verreault, Jean-Pierre
Al-Abed, Yousef
Foster, Warren
Akoum, Ali
author_facet Khoufache, Khaled
Bazin, Sylvie
Girard, Karine
Guillemette, Julie
Roy, Marie-Christine
Verreault, Jean-Pierre
Al-Abed, Yousef
Foster, Warren
Akoum, Ali
author_sort Khoufache, Khaled
collection PubMed
description Endometriosis, a disease of reproductive age women, is a major cause of infertility, menstrual disorders and pelvic pain. Little is known about its etiopathology, but chronic pelvic inflammation is a common feature in affected women. Beside symptomatic treatment of endometriosis-associated pain, only two main suboptimal therapeutic approaches (hormonal and invasive surgery) are generally recommended to patients and no specific targeted treatment is available. Our studies led to the detection of a marked increase in the expression of macrophage migration inhibitory factor (MIF) in the eutopic endometrium, the peripheral blood and the peritoneal fluid of women with endometriosis, and in early, vascularized and active endometriotic lesions. Herein, we developed a treatment model of endometriosis, where human endometrial tissue was first allowed to implant into the peritoneal cavity of nude mice, to assess in vivo the effect of a specific antagonist of MIF (ISO-1) on the progression of endometriosis and evaluate its efficacy as a potential therapeutic tool. Administration of ISO-1 led to a significant decline of the number, size and in situ dissemination of endometriotic lesions. We further showed that ISO-1 may act by significantly inhibiting cell adhesion, tissue remodeling, angiogenesis and inflammation as well as by altering the balance of pro- and anti-apoptotic factors. Actually, mice treatment with ISO-1 significantly reduced the expression of cell adhesion receptors αv and ß3 integrins (P<0.05), matrix metalloproteinases (MMP) 2 and 9 (P<0.05), vascular endothelial cell growth factor (VEGF) (P<0.01), interleukin 8 (IL8) (P<0.05), cyclooxygenease (COX)2 (P<0.001) and the anti-apoptotic protein Bcl2 (P<0.01), but significantly induced the expression of Bax (P<0.05), a potent pro-apoptotic protein. These data provide evidence that specific inhibition of MIF alters endometriotic tissue growth and progression in vivo and may represent a promising potential therapeutic avenue.
format Online
Article
Text
id pubmed-3359359
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33593592012-05-30 Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo Khoufache, Khaled Bazin, Sylvie Girard, Karine Guillemette, Julie Roy, Marie-Christine Verreault, Jean-Pierre Al-Abed, Yousef Foster, Warren Akoum, Ali PLoS One Research Article Endometriosis, a disease of reproductive age women, is a major cause of infertility, menstrual disorders and pelvic pain. Little is known about its etiopathology, but chronic pelvic inflammation is a common feature in affected women. Beside symptomatic treatment of endometriosis-associated pain, only two main suboptimal therapeutic approaches (hormonal and invasive surgery) are generally recommended to patients and no specific targeted treatment is available. Our studies led to the detection of a marked increase in the expression of macrophage migration inhibitory factor (MIF) in the eutopic endometrium, the peripheral blood and the peritoneal fluid of women with endometriosis, and in early, vascularized and active endometriotic lesions. Herein, we developed a treatment model of endometriosis, where human endometrial tissue was first allowed to implant into the peritoneal cavity of nude mice, to assess in vivo the effect of a specific antagonist of MIF (ISO-1) on the progression of endometriosis and evaluate its efficacy as a potential therapeutic tool. Administration of ISO-1 led to a significant decline of the number, size and in situ dissemination of endometriotic lesions. We further showed that ISO-1 may act by significantly inhibiting cell adhesion, tissue remodeling, angiogenesis and inflammation as well as by altering the balance of pro- and anti-apoptotic factors. Actually, mice treatment with ISO-1 significantly reduced the expression of cell adhesion receptors αv and ß3 integrins (P<0.05), matrix metalloproteinases (MMP) 2 and 9 (P<0.05), vascular endothelial cell growth factor (VEGF) (P<0.01), interleukin 8 (IL8) (P<0.05), cyclooxygenease (COX)2 (P<0.001) and the anti-apoptotic protein Bcl2 (P<0.01), but significantly induced the expression of Bax (P<0.05), a potent pro-apoptotic protein. These data provide evidence that specific inhibition of MIF alters endometriotic tissue growth and progression in vivo and may represent a promising potential therapeutic avenue. Public Library of Science 2012-05-23 /pmc/articles/PMC3359359/ /pubmed/22649515 http://dx.doi.org/10.1371/journal.pone.0037264 Text en Khoufache et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Khoufache, Khaled
Bazin, Sylvie
Girard, Karine
Guillemette, Julie
Roy, Marie-Christine
Verreault, Jean-Pierre
Al-Abed, Yousef
Foster, Warren
Akoum, Ali
Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo
title Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo
title_full Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo
title_fullStr Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo
title_full_unstemmed Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo
title_short Macrophage Migration Inhibitory Factor Antagonist Blocks the Development of Endometriosis In Vivo
title_sort macrophage migration inhibitory factor antagonist blocks the development of endometriosis in vivo
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3359359/
https://www.ncbi.nlm.nih.gov/pubmed/22649515
http://dx.doi.org/10.1371/journal.pone.0037264
work_keys_str_mv AT khoufachekhaled macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT bazinsylvie macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT girardkarine macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT guillemettejulie macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT roymariechristine macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT verreaultjeanpierre macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT alabedyousef macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT fosterwarren macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo
AT akoumali macrophagemigrationinhibitoryfactorantagonistblocksthedevelopmentofendometriosisinvivo